This review provides an update of the recent progress in etiology, pathogenesis, diagnosis, and treatment of osteonecrosis.
Introduction
There continue to be significant gaps in our knowledge concerning the pathogenesis, natural history, early diagnosis, and optimal treatment of osteonecrosis. Research is impeded, in part, due to the relatively low incidence of the disease and the several etiologic associations that have been identified. As a consequence, there is also considerable disagreement on how and when to treat these patients. Several intriguing papers were published in 2003 that may lead to a better understanding of this disease, the ability to better identify at-risk patients, and the development of future treatment alternatives.
Natural history
The true natural history of osteonecrosis can only be fully understood by following patients who have not received intervening treatment. A close substitute is following patients who have received only conservative treatment (ie, limited weight bearing). Additionally, as different causes may involve different pathogenetic mechanisms, it is important to observe patients with different etiologic associations to determine whether the natural history is the same for all patients.
Ito et al. [1•] studied the natural history of osteonecrosis by following lesions in the contralateral hip of patients in whom unilateral symptomatic collapse had originally been diagnosed (60 hips in 60 patients) or by screening patients with collagen disease (30 hips, 17 patients). Follow-up ranged from 5 to 16 years (mean, 9 years) . Using the Steinberg classification system, there were 39 stage I hips, 40 stage II, and 11 stage III. Failure was defined as a Harris hip score of <70. Overall, there was 60% success at 1 year, 43.3% at 2 years, 38.9% at 5 years, and 37.2% at 10 years. In one patient, progression was not detected until 90 months from the initial diagnosis. Evidence of a reduction in the size of the lesion was observed in 36% of the cases.
Previous investigators have suggested that repeated episodes of osteonecrosis may occur. Kim et al. [2•] documented three cases of recurrent osteonecrosis. In one patient, a new dense necrotic line was noted on MR scans outside the original sclerotic line at 6 months that had thickened by 1 year. The authors admit that although recurrent osteonecrosis does occur, it is rare.
The natural history of osteonecrosis in patients with sickle cell disease was characterized by Hernigou et al.
[3•]. They studied 92 symptomatic hips in 64 patients with a mean duration of 17 years. Patients without collapse did not receive any treatment during the period of study. Of the hips that did not have collapse initially, 87% collapsed within 5 years of diagnosis. Of the 32 Steinberg stage I hips, radiographic progression was seen in 12 at 1 year, 20 by 2 years, and 30 by 3 years. Collapse was seen in one patient at 1 year, nine at 2 years, and 14 at 3 years. Eight did not collapse until after 5 years. All stage II, III, and IV progressed to collapse, with stage II collapsing by an average of 30 months and stage III and IV collapsing within 18 months. The findings in this study suggest that osteonecrosis with sickle cell disease has an even poorer prognosis than non-sickle cell associated osteonecrosis.
Etiology
Over the past decade, there has been increasing evidence that intravascular coagulation may play a role in the pathogenesis of osteonecrosis [4•,5] . Two conflicting reports were published on this topic in 2003. Jones et al. [6•] reported that 82% of the osteonecrosis patients evaluated had at least one coagulation abnormality as compared with 30% of the controls. Forty-seven percent of the osteonecrosis patients had two or more abnormalities. Specifically, more osteonecrosis patients were likely to have elevated plasminogen activator inhibitor activity (42%) or elevated anticardiolipin antibody IgG (34%). In contrast, Lee et al. [7•] were unable to detect any significant differences between osteonecrosis patients and matched controls in the levels of thrombotic and fibrinolytic factors or the number of patients with abnormal values. The reasons for the discrepancies between these two reports are unclear. Lee et al. suggest that this may reflect ethnic differences. However, it may also be influenced by differences in analytical techniques, experimental design, or data analysis.
An increasing number of reports document a relationship between HIV infection and osteonecrosis [8,9,10•,11•] . Valencia et al. [11•] suggest that a cause and effect relationship is difficult to establish, because many of the patients have numerous risk factors already associated with osteonecrosis (eg, corticosteroid treatment, smoking, alcoholism, hyperlipidemia, and hyperviscosity). There is conflicting evidence relating antiretroviral therapy, particularly protease inhibitors, to the development of osteonecrosis.
The mechanism(s) involved in the pathogenesis of alcohol-associated osteonecrosis remain theoretical. In a rabbit model, Wang et al. [12••] studied the effect of alcohol administered daily for up to 6 months. Alcohol treatment resulted in elevations of serum lipid peroxides, triglyceride, and cholesterol and a reduction in superoxide dismutase. They noted many pathologic changes also associated with human osteonecrosis including diminished hematopoiesis, increased fat cell hypertrophy and proliferation, increased lipid deposition in osteocytes within the subchondral region of the femoral head, and an increased number of empty osteocyte lacunae. In an in vitro study, they found that alcohol can induce pluripotential bone marrow stromal cells to differentiate into adiocytes, thereby decreasing osteogenesis.
Genetic predisposition
In a study of alcoholic patients with hip osteonecrosis, Chao et al. [13•] propose that genetic polymorphisms may influence whether a patient develops osteonecrosis. Polymorphisms of several alcohol-metabolizing enzymes were evaluated in alcoholics with hip osteonecrosis, pancreatitis, cirrhosis of the liver, and combinations thereof. With respect to liver alcohol dehydrogenase, the alleles ADH2*1 and ADH2*2 were evaluated. The frequency of the allele ADH2*1 was significantly lower for the osteonecrosis group as compared with the cirrhosis group but not the pancreatitis group. However, it was more common to have both osteonecrosis and cirrhosis than osteonecrosis and pancreatitis. The investigators suggest that this discrepancy may be a consequence of other genetic variations within these patient subpopulations.
High-dose corticosteroid therapy is a significant risk factor for osteonecrosis. Once again, not all patients with this specific risk factor develop the disease. The reasons for this relationship remain unknown. Asano et al. [14••] suggested that the drug-transport protein P-glycoprotein may play a discriminating role. In a patient base of 136 kidney transplant patients, they studied 30 patients who developed osteonecrosis and compared them with 106 patients who did not. They evaluated single-nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1, MDR1). Patients with the ABCB1 3435TT genotype showed a significantly lower incidence of osteonecrosis. The incidence of osteonecrosis was higher in patients following the large-dose protocol. They also provided evidence that the pump activity of P-glycoprotein is increased in 3435TT and, therefore, might result in increases in intracellular steroid concentrations in specific tissues. This information may affect not only our understanding of the pathogenetic mechanisms of steroid-associated osteonecrosis but also our ability to identify at-risk patients.
Diagnosis

MRI/CT scanning
The application of MRI to osteonecrosis revolutionized the ability to diagnose the preradiographic stages of this disease. Although MRI is now considered the gold standard, studies continue to explore the boundaries of its use. As lesion size has been implicated as influencing prognosis, the method used to determine lesion area or volume using MRIs is important. Stevens et al. [15•] found that CT scanning, using a helical scanner, identi-fied more subchondral fractures than either radiography or MRI. Compared with CT scanning, radiography and MRI were less sensitive (71% and 38%, respectively). In contrast, Cherian et al. [16•] found that the index of necrotic extent measured on MRI, as described by Koo et al. [17] , was a significant predictor of time to collapse. The technology surrounding MRI continues to evolve. A more accurate and detailed assessment of lesion size may be available with three-dimensional spoiled gradientecho MRI, with the added advantage of shortened imaging time and the associated cost savings [18••] . Other modifications of MR technology, such as the use of serial repetitive T2*-weighted dynamic MRI, may be used to evaluate femoral perfusion and thereby detect osteonecrosis at earlier stages [19•].
Current treatments
Joint preserving
Different approaches have been undertaken to preserve the joint by preventing collapse, primarily by supporting the underlying subchondral bone. These have included both vascularized and nonvascularized bone grafting procedures, cementation, and implantation of porous metal rod (trabecular metal). Short-term results have been favorable for most of these procedures, but less is known about the long-term success.
Cementation
In 1993, Hernigou et al.
[20] described a procedure in which they reduced the collapsed segment with a pin and then injected low-viscosity cement into the necrotic femoral heads of 16 patients with sickle cell disease. Although the 5-year results were promising, no further reports on the long-term results of this series have been published. Using a modification of this procedure, Wood et al. [21] reported poor results with large lesions (ARCO stage III C disease) and good results with smaller (stage IIIB) lesions. Although the authors recommend this procedure for symptomatic, young patients with mild to moderate stage III disease, long-term follow-up is needed.
Bone grafting
Nonvascularized bone grafting procedures for the treatment of osteonecrosis have ranged from filling the core tract during core decompression procedures to filling the residual defect after removing the entire necrotic segment. A study of bone impaction grafting indicated that 29% of the hips were converted to total hip arthroplasty (THA) at a mean follow-up of 23 months (range, 13-39 months) [22] . This study also showed radiographic progression in most hips. It is possible that the results are influenced by lesion size: all were large lesions (combined necrotic angle >200°). The authors conclude that improvements in the technique are necessary. Using a modified trap-door procedure and BMP-enriched allograft (OpteForm, Exactech, Gainesville, FL), Mont et al.
[23•] reported clinically successful outcomes in 86% of the hips at a mean follow-up of 48 months (range, 36-55 months). All small lesions were successful, whereas 11 of 14 patients with larger lesions were successful.
There has been increasing interest in the use of vascularized fibular grafting for the treatment of osteonecrosis. Although previous studies have shown that this procedure can be successfully used in precollapse hips, Berend et al. [24••] have now reported survival rates of 75% at 3 years and 65% at 5 years for postcollapse hips. Plakseychuk et al. [25•] also found that the mid-term clinical results for vascularized fibular grafts were better than nonvascularized grafts, especially in the precollapse group (86% vs 30%, respectively). However, significant complications were noted in 26% of vascularized graft patients as compared with 8% for the nonvascularized group. Heterotopic ossification is also a frequent complication of this procedure [26] . Concern has also been raised about the potential impact of this surgery on future surgical treatments. Beaulé et al. [27] published a case report of a successful hemiresurfacing procedure (cemented) at 2-year follow-up. In a study evaluating total joint replacement following a failed vascularized fibular graft, Berend et al. [28] reported survival rates of 94.4% at 5 years and 85.4% at 10 years (using revision as failure). Only four hips (7.4%) were revised for loosening. However, only 52% had good or excellent results as determined by HHS obtained through phone surveys. The implications of this finding need to be evaluated further.
Other adaptations of vascularized bone grafting have also been evaluated. At 5-and 10 year follow-up, Hasegawa et al. [29•] reported higher survival rates for patients with iliac pedicle bone grafting (85%, 67%, respectively) as compared with patients with transtrochanteric rotational osteotomy osteotomy (71%, 61%, respectively). However, this may be a reflection of the significantly larger percentage of stage III patients in the later group. No major complications were detected for the grafting group as compared with several in the osteotomy group (deep infection, trochanteric fractures, pseudarthrosis, progressive collapse). Fuchs et al. [30] described their experience with a combination of femoral osteotomy and pedicled iliac block transfer in patients with Ficat II or III disease. Long-term follow-up (mean 13.5 years, 5-20 years) was available for 44 hips. About one-third failed and were converted to THA. Of the hips that did not fail, 69% progressed to another stage. There were a significant number of complications including postoperative hematoma requiring revision, meralgia paresthetica, nonvascular graft at time of insertion, nonunion of the intertrochanteric osteotomy, derotation of the osteotomy, and total collapse of the femoral head. The authors suggest that this procedure is recommended only for Ficat stage II disease. However, other less technically demanding procedures appear to have better results and significantly less morbidity for this stage of the disease.
Osteotomies
Regardless of approach, the goal of an osteotomy is to move the osteonecrotic lesion away from the weightbearing area of the joint. The application of osteotomy to the treatment of osteonecrosis has declined because of the low success rate, significant complication rate, and the resultant anatomic deformations to the femur that may compromise future surgery. Although Drescher et al. 
Arthroplasty procedures Femoral head resurfacing
Improvements in prosthetic design and surgical technique have led to a recent resurgence in the use of hemiresurfacing arthroplasty to treat osteonecrosis. Adili and Trousdale [33•] report survivorship rates of 93.5% at 1 year and 75.9% at 2 and 3 years for this procedure (failure defined as revision). Using Harris hip scores, they report only 42.8% with good or excellent results. The authors note that the fair or poor results were in patients with multiple joint involvement. However, they are in agreement with previous investigators who suggest that hemiresurfacing arthroplasty is an interim treatment for young patients with large necrotic lesions.
Total hip arthroplasty
Historical reviews of THA in patients with osteonecrosis have had significantly worse results than comparable series in osteoarthritic patients [34] [35] [36] . Recently, there is growing evidence that the overall results for osteonecrosis patients have improved and are indistinguishable from other patient populations [37, 38] .
Kim et al. [39•] evaluated 98 consecutive patients with an average follow-up of 9.3 years. Fifty patients had bilateral THA with cemented fixation in one hip and cementless fixation of the contralateral hip; 48 patients had unilateral cementless THA. The average Harris hip scores at final follow-up were similar for the two groups (96 points, cemented; 95 points, cementless). There was no definite aseptic loosening in either the cemented or cementless groups, whereas two cemented stems had evidence of possible loosening. Only three stems were revised: one cemented for infection and two cementless for fracture of the proximal femur. However, concern was raised about the relatively young age (mean, 47.3 years) of the patient population and the high rate of osteolysis detected in the proximal region in 16% of the cemented group and 24% in the cementless group.
Ceramic-on-ceramic total hip prostheses have been introduced as an alternative to metal-on-polyethylene prostheses, as they have negligible wear of the articulating surfaces. Nich et al. [40•] reported on a series of 52 consecutive THAs in 41 patients with osteonecrosis. All femoral stems were fixed using cement. Sixteen hips (12 patients) were revised at a mean of 11.1 years (range, 2.7-19.7 years). While most revisions were for aseptic loosening of the acetabular component, the femoral component was revised in four cases for aseptic loosening of the femur. With respect to revision of the femoral component for aseptic loosening, there was a 100% survival rate at 10 years and a 96.7% survival rate at 16 years.
Future treatments
Hyperbaric oxygen
Inhalation of hyperbaric oxygen (HBO) results in increased amounts of tissue oxygenation and has been shown to promote synthesis of collagen, fibroblast proliferation, and capillary angiogenesis [41•]. Although most of the previous studies have involved the treatment of postradiation necrosis of the jaw or pediatric applications, the results have indicated long-term improvement in patients with early osteonecrosis following HBO therapy. Reis et al. [41] report that necrotic lesions of Steinberg stage I disease that were of a specific size (Ն4 mm thick or Ն12.5 mm long) were either healed (81%) or progression impeded (12.5%) following HBO therapy. Progression to collapse was noted in only one of 16 lesions. The limitations of this procedure appear to be the relatively high cost (estimated at $10,000) and commitment of time necessary (100 sessions).
Pharmaceuticals
The search for a pharmaceutical treatment for osteonecrosis has been directed towards altering one of the potential pathogenetic mechanisms. This has included attempts to diminish hypertension, adipogenesis, or coagulation disorders.
Cui et al. [42] and Wang et al. [43] have suggested that the lipid-clearing agent lovastatin may be effective in the treatment of osteonecrosis. To evaluate the mechanism of action of lovastatin, Li et al. [44•] treated a multipotential cell line, D1, with dexamethasone and lovastatin. This resulted in an increased expression of the bone cell transcription factor Cbfa1/Runx2, an increase in osteocalcin promoter activity, and a concomitant decrease in the expression of fat cell transcription factor PPAR 2. These findings indicate that lovastatin may counteract the dexamethasone-induced differentiation of bone marrow mesenchymal cells into adipocytes and shift the differentiation towards osteoblast formation. This treatment may have an impact on decreasing fat cell proliferation and bone loss in patients with corticosteroid-associated osteonecrosis.
With respect to coagulation disorders in osteonecrosis patients, Glueck et al. [4•] have evaluated the effect of low-molecular-weight heparin (enoxaparin; 60 mg/d for 12 weeks) on 23 patients with early osteonecrosis in whom heritable thrombophilia and hypofibrinolysis had also been diagnosed. With a minimum of 2-year followup, treatment failed in nine patients before 108 weeks, while nine patients had no progression of their disease. The remaining five patients had shorter follow-up times (72 weeks, n = 1; 36 weeks, n = 4). No progression was observed for these patients. As the natural history is so variable between patients with only conservative treatment and the risks of adverse events are notable, it is important that this study be continued with greater numbers of patients, longer periods, and matched controls.
Cell-based or gene therapy
As with other musculoskeletal diseases, future treatments for osteonecrosis may involve tissue engineering. This may involve cell-seeded scaffolds, controlledrelease scaffolds, or gene therapy. The application of these technologies to osteonecrosis has just begun.
Lee et al. [45•] reported that they were able to isolate multipotential mesenchymal stem cells (MSCs) from the bone marrow of two patients with osteonecrosis who were undergoing total hip replacement (THR). After continuous culture for 1 to 2 weeks, more than 20 colonies of spindle-shaped fibroblastic cells, homogeneously positive for ␤1-integrin, were obtained from the primary cultures. Depending on culturing conditions, these cells were capable of chondrogenic or osteogenic differentiation. The authors conclude that enriched multipotential MSCs isolated from the marrow of proximal femurs are a potential source of cells that can be used for replacement therapy of osteochondral defects either by direct autologous transplantation of the sorted cells or transplantation of the cells coaxed in a biocompatible vehicle.
Growth factors may have a role in the treatment of osteonecrosis [46] . One candidate is vascular endothelial growth factor (VEGF), which has been shown to stimulate angiogenesis and promote healing. With the clinical application of cytokine and growth factors to treat disease, concerns have arisen pertaining to their biologic activity, their effective half-lives, and the substrate used to introduce or anchor the biomaterial to the area of interest. Another novel approach to this is to use gene transfection. Yang et al. [47••] have investigated the use of a recombinant plasmid pCD-hVEGF165 mixed with collagen for the treatment of an animal model of osteonecrosis. Bone necrosis of the entire femoral head was accomplished using a freezing technique. The pCD-hVEGF165 plasmid mixture was introduced through a drill hole in the femoral head. VEGF mRNA was detected in the femoral head at 2 weeks but not at 4 weeks. Higher percentages of new vessels and new bone were evident in the treated group as compared with the two control groups. In the plasmid-treated group, in addition to the natural repair of the necrosis at the dead bone/live bone interface, new bone was observed in the channel of the drill hole and on the surface of the dead trabeculae. This exciting finding warrants additional research concerning the optimal dose, the effect on smaller lesions, and the long-term effect.
Conclusion
In 2003, research continues to chip away at our lack of understanding concerning the natural history, pathogenesis and etiology, and diagnosis and treatment of osteonecrosis. Studies have confirmed that the rate of progression of osteonecrosis is variable and is, in part, influenced by a patient's etiologic associations. Recurrent episodes can occur, but the incidence is rare. Studies continue to explore pathogenetic mechanisms involved with different etiologies. Alcohol-associated osteonecrosis may involve promotion of differentiation of precursor cells into adiopyctes or differences in alcohol-metabolizing enzymes. Of major interest is the finding that patients with specific genotypes relating to the metabolism of alcohol or corticosteroids may be at greater risk to develop the disease. There is a relatively high incidence of osteonecrosis in patients with HIV, but whether this is related to the comorbidities, corticosteroid therapy, or antiviral therapy is still open to debate. The debate continues as to what role coagulopathies play in the pathogenesis of this disease. Improvements in diagnostic tools may permit the diagnosis of osteonecrosis in the presymptomatic state as well as more accurate determination of the extent of the necrotic lesions. One group has provided evidence that CT scanning may be better for identifying early subchondral lesions as compared with current MRI technique. However, the diagnostic ability of MRI may be improved using three-dimensional spoiled gradient-echo MRI while also reducing imaging time and cost.
Treatment for osteonecrosis ranges from pain relief and protected weight bearing to total joint replacement. The clinical results of joint-sparing procedures continue to be uneven. Most efforts to preserve the femoral head are effective in small, early-stage lesions; but for larger lesions and in more advanced disease, success rates in the 2-to 5-year window remain locked in at 60% to 70%. Although bone graft substitutes theoretically may improve the outcomes of attempts to replace the necrotic segment and support the collapsing subchondral plate, demonstration of their ultimate success remains. Although free vascularized fibular grafts enjoy a higher success rate compared with other bone grafting methods, they come at the cost of higher complication rates and more difficult conversion if THR becomes necessary. The success of repositioning osteotomy is also similar to bone grafting techniques and has the additional deficit in that it deforms the femur and makes subsequent THR more difficult and more hazardous. The decision to use a specific procedure is dependent on stage and extent of disease, as well as an assessment of risk/benefit. In general, the clinical results of THA have improved with improvements in prosthesis design and surgical technique. This is even more apparent for patients with osteonecrosis. The results for THA in osteonecrosis patients are significantly improved over those reported 10 to 15 years ago. In fact, results in these patients are now similar to those of patients with other diseases such as osteoarthritis.
The future of osteonecrosis is dependent on identifying at-risk patients and an improved understanding of the pathogenetic mechanisms involved. We need to continue to conduct studies on potential pharmaceutical treatments for osteonecrosis patients, either for treating the disease itself or for the treatment of coexisting conditions. Advances in gene therapy and cell-based therapy may lead to new treatment alternatives in the not-sodistant future.
It is imperative that we continue to characterize the natural history and study potential pathophysiological mechanisms in the development of osteonecrosis. Within this context we will be able to determine the efficacy of treatment modalities. The potential to identify at-risk patients may ultimately lead to the prevention of this disease.
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